hydroxyurea + naproxen + dasatinib

**Hydroxyurea + naproxen + dasatinib** is a specific combination of three distinct pharmaceutical agents not established as a single approved product or standard regimen. Hydroxyurea is a cytotoxic antimetabolite that inhibits ribonucleotide reductase, reducing DNA synthesis primarily for myeloproliferative disorders and sickle cell disease. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that nonselectively inhibits cyclooxygenase (COX-1 and COX-2) enzymes to block prostaglandin synthesis, used for pain and inflammation. Dasatinib is an oral multikinase inhibitor targeting BCR-ABL tyrosine kinase and SRC family kinases, approved for Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). No developer or primary indication exists for this exact combination; potential use might relate to experimental antileukemic therapy with supportive pain management, but interactions include bleeding risks from dasatinib-induced thrombocytopenia combined with naproxen's antiplatelet effects and hydroxyurea's myelosuppression.